Dopamine Receptor 1 Treatment Promotes Epithelial Repair of Corneal Injury by Inhibiting NOD-Like Receptor Protein 3–Associated Inflammation
Open Access
- 2 January 2024
- journal article
- research article
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 65 (1) , 49
Abstract
Purpose: To elucidate the influence of dopamine receptor 1 (DRD1) on the proliferation of mouse corneal epithelial cells (MCECs) under inflammatory conditions. Methods: In vitro, immortalized MCECs (iMCECs) were treated with IL-1β, with and without pcDNA3.1_DRD1. Primary MCECs (pMCECs) were exposed to IL-1β, with and without DRD1 agonist (A68930). Cell proliferation was quantified using the Cell Counting Kit-8 (CCK-8) assay and immunofluorescence staining for Ki-67 and p63. Expression levels of NOD-like receptor protein 3 (NLRP3), IL-1β, and IL-6 were assessed. To establish a corneal injury model in mice, a 2-mm superficial keratectomy was performed. Either 0.1% A68930 or PBS was topically administered three times daily to the injured eyes for up to 5 days post-injury. Immunofluorescence analysis was employed to evaluate the expression of Ki-67, p63, and CD45 in mouse corneas. Western blotting and real-time quantitative PCR were utilized for quantitative analysis of DRD1, NLRP3, IL-1β, and IL-6 in mouse corneas. Corneal epithelial regeneration was monitored through fluorescein sodium staining for a duration of up to 5 days following the injury. Results: Overexpression of DRD1 and A68930 promoted MCEC proliferation and suppressed the expression of NLRP3, IL-1β, and IL-6 in vitro. Topical application of the 0.1% A68930 following mechanical corneal injury in mice led to increased Ki-67 and p63 expression compared to PBS treatment. Furthermore, topical administration of the 0.1% A68930 reduced the expression of CD45, NLRP3, IL-1β, and IL-6. Analysis with fluorescein sodium indicated accelerated corneal epithelial regeneration in the 0.1% A68930 treatment group. Conclusions: DRD1 treatment counteracts NLRP3-associated inflammation and facilitates epithelial repair of corneal injury.Keywords
This publication has 28 references indexed in Scilit:
- Corneal perforation secondary to gonococcal keratoconjunctivitisCanadian Medical Association Journal, 2020
- Dopamine D1 receptor agonist A68930 attenuates acute kidney injury by inhibiting NLRP3 inflammasome activationJournal of Pharmacological Sciences, 2020
- Corneal epithelial injury-induced norepinephrine promotes Pseudomonas aeruginosa keratitisExperimental Eye Research, 2020
- Topical Pergolide Enhance Corneal Nerve Regrowth Following Induced Corneal AbrasionInvestigative Ophthalmology & Visual Science, 2020
- Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantationProgress in Retinal and Eye Research, 2019
- Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathwayActa Pharmacologica Sinica, 2019
- A self-healing hydrogel eye drop for the sustained delivery of decorin to prevent corneal scarringBiomaterials, 2019
- Activation of dopamine D1 receptor decreased NLRP3-mediated inflammation in intracerebral hemorrhage miceJournal of Neuroinflammation, 2018
- Hepatocyte Growth Factor Suppresses Inflammation and Promotes Epithelium Repair in Corneal InjuryMolecular Therapy, 2017
- Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 InflammasomeCell, 2015